What capabilities matter most for a CDMO right after Phase 1?
At the Phase 1 scale-up point, you need a CDMO that can reliably move from lab/early clinical work into larger, repeatable batches while controlling risk to quality and timelines. Key signals include proven experience across the full drug-development lifecycle you need next (process development, tech transfer, clinical manufacturing), plus strong operational capacity to handle urgent scheduling without sacrificing documentation quality.
Can the CDMO scale your process quickly—or will you be stuck in tech transfer?
What to look for is evidence they can take your process from “works in early studies” to “works consistently at scale.” Ask whether they have:
- Documented tech-transfer experience from sponsor or internal R&D into production systems, including timelines and typical friction points.
- Process development/optimization capability (not only manufacturing) so improvements are possible as you learn from Phase 1.
- A clear plan for how they’ll lock the process parameters and analytical methods before later clinical stages.
Practically, you want a partner that treats scale-up and method/process alignment as an upfront workstream, not something that happens after you sign.
What should you demand on quality systems and regulatory readiness?
Even early clinical manufacturing must hold up under regulatory scrutiny. Look for:
- A quality system that supports GMP documentation, change control, deviations/CAPA, and batch record rigor.
- Analytical capability tied to release testing needs (identity, purity/impurities, potency or biological activity where relevant).
- Traceable material control and robust supplier qualification/qualification strategy, since raw material variability can create delays later.
Ask how they document and close out deviations and how often they miss planned delivery dates due to quality investigations rather than scheduling.
How fast can they ramp capacity, and what are the hidden causes of delay?
Timelines in CDMO engagements often slip due to facility lead times, analytical method readiness, material procurement, and internal scheduling conflicts. You should look for:
- Transparent capacity planning for both manufacturing and analytical testing (including turnaround times for CoA release).
- Planning discipline around long-lead items (key reagents, chromatography media, reference standards, consumables).
- Evidence of on-time delivery performance for similar programs and batch sizes.
Also ask what happens if your process or stability requirements change midstream (how they handle requalification, re-analysis, or reruns).
Do they have the right chemistry, formulation, and analytical expertise for your modality?
“Scale up” differs massively depending on whether you’re dealing with small molecules, biologics, oligonucleotides, or complex drug products. At this stage, the right match matters as much as generic GMP capability. Confirm:
- Domain expertise in your modality and dosage form (e.g., solid oral vs. sterile injectables; sterile fill-finish vs. non-sterile).
- Compatibility of their equipment, controls, and scale ranges with your process and target batch sizes.
- Analytical method maturity and whether they can support early method transfer from your team while maintaining validity.
If you’re unclear on what to ask, ask them to propose a development-and-scale plan with decision gates tied to what you must know before moving beyond Phase 1.
How should you evaluate their tech transfer approach and timeline assumptions?
Ask for a concrete tech transfer plan that includes:
- Inputs they need from you (process description, impurity profile, expected specifications, stability assumptions).
- Outputs they will produce (batch records, executed tech transfer protocol, method transfer documentation, validation/verification steps).
- Timing assumptions and dependencies (e.g., when analytical methods must be “good enough” for release).
You’re trying to avoid a common failure mode: manufacturing is ready, but the release assays are not, which blocks shipment and clinical dosing.
What contract terms protect you if your program changes mid-ramp?
At Phase 1 scale-up, program evolution is normal. Your CDMO should be able to support changes without collapsing timelines, but contract structure matters. Consider negotiating:
- Clarity on change control scope and timeline impact (especially for process parameters and analytical method changes).
- Run-of-schedule flexibility and how rescheduling fees or priority commitments work.
- Ownership and right-to-use arrangements for transferred documentation and methods.
- Clear responsibilities for comparability or bridging work if process changes affect critical attributes.
Make sure the contract reflects what you’re buying: not just “manufacturing slots,” but also development, transfer, and readiness to respond as you learn.
What “evidence” should you ask for before signing?
Beyond capabilities on paper, push for proof:
- Case studies or references with similar stage and scale (Phase 1-to-Phase 2 transition, or comparable ramp profiles).
- Their typical project plan structure (work breakdown, decision gates, deliverables).
- Quality KPIs you can understand (deviation rates, on-time delivery, audit outcomes).
- How they staff these projects (dedicated project manager, technical leads, QA coverage, analytical resources).
What red flags show up when companies pick the wrong CDMO at Phase 1?
Common warning signs include:
- They only emphasize manufacturing capacity but have limited process development/tech transfer support.
- Vague answers on timelines, method transfer readiness, or release testing turnaround.
- Poor transparency on how they handle deviations and reruns.
- A contract that treats program changes as exceptional rather than expected.
These are early indicators that you’ll pay later in delays, uncertainty, or rework.
What questions should you ask in the first partner meetings?
To get to decision-ready answers quickly, ask how they would run your ramp:
- What’s your proposed plan and timeline from current stage to next clinical delivery?
- What deliverables will you produce during tech transfer, and when?
- Which analytical methods will be transferred/qualified first, and what are the dependencies?
- How do you manage long-lead materials and stability/packaging needs?
- How do you maintain on-time delivery when schedule changes happen?
If you want a fast, practical next step, ask them to propose a phased plan (e.g., readiness milestone, process locking milestone, method readiness milestone, first full clinical batch, then scale adjustment if required) and explain what inputs they need from you at each stage.
Sources
No external sources were provided with your question.